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We report the outcome of 12 consecutive pediatric patients with Fanconi anemia (FA) who had neither an
HLA-identical sibling nor an HLA-matched unrelated donor and who were given T celledepleted, CD34þ
positively selected cells from a haploidentical related donor after a reduced-intensity, ﬂudarabine-based
conditioning regimen. Engraftment was achieved in 9 of 12 patients (75%), and the cumulative incidence of
graft rejection was 17% (95% conﬁdence interval [CI], 5% to 59%). Cumulative incidences of grades II to IV acute
and chronic graft-versus-host disease were 17% (95% CI, 5% to 59%) and 35% (95% CI, 14% to 89%), respectively.
The conditioning regimen was well tolerated, with no fatal regimen-related toxicity and 3 cases of grade III
regimen-related toxicity. The cumulative incidence of transplant-related mortality was 17% (95% CI, 5% to
59%). The 5-year overall survival, event-free survival, and disease-free survival were 83% (95% CI, 62% to
100%), 67% (95% CI, 40% to 93%), and 83% (95% CI, 62% to 100%), respectively. These data demonstrate that a
ﬂudarabine-based conditioning regimen, followed by infusion of high doses of T celledepleted stem cells, is
able to ensure engraftment with good overall survival and disease-free survival, conﬁrming the feasibility of
haploidentical hematopoietic stem cell transplantation in FA. To the best of our knowledge, this is the largest
series of hematopoietic stem cell transplantation from a haploidentical related donor in FA patients reported
to date.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Fanconi anemia (FA) is a genetically and phenotypically
heterogeneous disorder characterized by the variable pres-
ence of multiple congenital somatic abnormalities, the
gradual onset of bone marrow failure involving one or more
hematopoietic cell lineages, and predisposition to develop
clonal hematopoietic disorders, as well as solid tumors,
mostly head and neck squamous-cell carcinomas [1-5]. On a
cellular level, FA is characterized by chromosome fragility
and hypersensitivity to DNA interstrand cross-linking agents.
With an incidence of approximately 1 out of 100,000 births
per year, it is the most common cause of constitutional bone
marrow failure [6].
FA is caused by germline mutations, inherited in an
autosomal (or rarely X-linked) recessive pattern. To date, 15
genes are known to be involved in FA pathogenesis [7,8], and
because patients with mutations in any of these genes share
a characteristic cellular and clinical phenotype, they have
been postulated to interact in a common cellular pathway
involved in DNA repair processes, known as the FA pathwayedgments on page 575.
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14.01.015[9]. More recently, using whole-exome and Sanger se-
quencing on DNA of 2 unclassiﬁed FA patients, Bogliolo et al.
[10] identiﬁed ERCC4 (Xeroderma pigmentosum group F) as
an additional FA-associated gene, thus called FANCQ.
Optimized supportive care, including RBC/platelet trans-
fusions, androgen therapy, recombinant growth factors, and
prevention/treatment of infectious complications, is a critical
aspect of conservative management of FA patients once
advanced marrow failure occurs [11]. Allogeneic hemato-
poietic stem cell transplantation (HSCT) is currently the only
therapeutic option able to restore normal hematopoiesis in
patients with FA, with the potential for deﬁnitively cor-
recting the occurrence of marrow failure associated with
the disease and for preventing/treating myeloid malig-
nancies, although it does not affect the congenital defects
in other tissues and cannot prevent the late occurrence of
solid tumors. Initial attempts at HSCT for FA patients yielded
poor results, mainly due to the underlying defect in DNA
repair and hypersensitivity to treatment with irradiation
and cytotoxic agents, such as cyclophosphamide (Cy), lead-
ing to excessive regimen-related toxicity and severe acute
graft-versus-host disease (GVHD) [12,13]. Pretransplantation
conditioning regimens speciﬁcally developed for FA patients
and based on the use of low-dose Cy and limited-ﬁeld irra-
diation (thoracoabdominal irradiation) have met with some
success [14].Transplantation.
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tients transplanted from an HLA-identical sibling donor [14-
16], results from alternative donor transplantations have
been less encouraging [14]. Nonetheless, over the past 2 de-
cades signiﬁcant improvements in alternative donor HSCT
have been achieved, mainly due to the optimization of HLA
typing for donor selection, conditioning regimens, with
ﬂudarabine (Flu) playing a pivotal role [16], and to the
introduction of T celledepletion techniques for graft mani-
pulation, making indications to transplantation in FA quite
consistent regardless of the donor used.
Notwithstanding some encouraging results and potential
beneﬁts of allogeneic HSCT from an HLA partially matched
related donor in FA patients, current evidence in the medical
literature is limited to case reports and small retrospective
case series [14,17-26]. The present study describes the out-
comes of 12 consecutive pediatric FA patients who under-
went T celledepleted (TCD) HSCT from an HLA partially
matched relative, after a Flu-based preparative regimen.METHODS
Data Collection
Data concerning patient, disease, graft characteristics, transplantation
outcomes, and follow-up were collected by means of standardized data
collection forms for each patient.Patients
Twelve consecutive patients affected by FA received a TCD peripheral
blood stem cell allograft from an HLA-haploidentical related donor between
July 2001 and June 2012 at 2 Italian pediatric HSCTcenters (Pavia and Rome).
Details on patient, donor, and transplantation characteristics are reported in
Tables 1 and 2. Three of 12 patients (patients 1, 4, and 5, Table 1) have been
already described in previously published reports [20,23]. Written informed
consent was obtained from all patients or from their parents/legal guardians
in accordance with the Declaration of Helsinki.
The patients, 8 girls and 4 boys, ranged in age from 5.9 to 21.7 years
(median, 8.6) at time of transplantation. FA diagnosis was conﬁrmed by
means of diepoxybutane-induced chromosome breakage assay in all cases.
Median age at diagnosis was 6.7 years (range, 2.7 to 12.4), and median time
from diagnosis to HSCT was 2.4 years (range .3 to 19.0).Table 1
Details of the 12 Patients, Follow-Ups, and Transplant Outcomes
Patient
No.
Sex Age at
Diagnosis (yr)
Age at
HSCT (yr)
Diagnosis
HSCT (yr)
Disease Status No. of HSCT
Received
1 F 9.0 15.3 6.4 Transfusion
dependent
1
2
2 M 4.1 8.5 4.4 Transfusion
dependent
1
3 F 8.5 9.2 .7 Transfusion
dependent
1
4 F 2.7 8.3 5.6 Transfusion
dependent
1
5 F 3.0 6.3 3.3 Transfusion
dependent
1
6 F 5.8 8.0 2.2 Transfusion
dependent
1
7 F 7.5 8.7 1.2 Transfusion
dependent
1
8 M 4.9 5.9 1.0 Transfusion
dependent NHL
1
2
9 M 12.4 12.8 .3 Transfusion
dependent
1
10 M 5.9 6.7 .8 Transfusion
dependent
1
11 F 9.0 28.7 19.7 Transfusion
dependent AML
1
12 F 7.4 10.0 2.6 Transfusion
dependent
1
RSV, respiratory syncytial virus; NHL, non-Hodgkin lymphoma; AML, acute myeloAt timeof transplantation, all patientswereRBCand/or platelet transfusion
dependent, butnopatient had severe ironoverloadorwas refractory to platelet
transfusions.Nopatient inourcohorthadahistoryofandrogenexposurebefore
transplant. Two patients had evidence of clonal evolution at time of ﬁrst eval-
uation. Patient 8 was diagnosed with both myelodysplastic syndrome with
chromosome 5q31 deletion and chromosome 17p13.1 deletion involving the
TP53 tumor suppressor gene and T cell non-Hodgkin lymphoma (serology
showed positive viral capsid antigen and Epstein-Barr nuclear antigen IgG and
negative viral capsid antigen IgM, whereas blood Epstein-Barr virus-DNAwas
negative)andwastreatedwithachemotherapyregimenconsistingof low-dose
Flu (25mg/m2/day for2days), L-asparaginase (10,000U/m2/day for4days), and
dexamethasone (20mg/m2/day for 4 days) with a remarkable reduction of the
mediastinal mass at time of HSCT. Patient 11 had acute myeloid leukemiawith
a complex karyotype, namely 46,XX,der(6)t(6;?),der(7)t(7;?),der(15)t(15;?),
der(16)t(16;?),der(18)t(18;?), and was successfully induced into remission
before HSCT through 2 chemotherapy cycles consisting of Flu, cytosine arabi-
noside, and liposomal doxorubicine. In all patients, high-resolution molecular
typing was performed to characterize HLA class I and II loci.
Donors
Donors were HLA-typed using low-resolution DNA methods for HLA-A
and HLA-B loci and high-resolution molecular typing at HLA-C and HLA
class II loci. All donors were ﬁrst-degree relatives, completely matched with
the patient at 1 haplotype, with second haplotype mismatches detailed as
follows. Eleven of 14 donors were full-haplotype mismatched (HLA-A, -B, -C,
and -DR antigen mismatches); in 2 cases 3 mismatches on the antigen level
and 1mismatch on the allele level (HLA-Aor -C)were present; in 1 case donor
and recipient were different for 3 HLA loci and matched for HLA-DR. Seven of
14 donorswere killer immunoglobulin-like receptor (KIR)-ligandmismatched
with the respective recipient.Mediandonoragewas41 years (range, 30 to 58),
with mothers and fathers used in 5 and 7 cases, respectively.
Donor selection was based on the following algorithm. First, a natural
killer (NK)-alloreactive donor, according to the KIR/KIR ligand mismatch
model, was chosen by virtue of the effect of donor NK cell alloreactivity on
prevention of GVHD and graft rejection [27]. Second, the mother was
selected if no NK-alloreactive donor was available because better outcomes
have been reported in parent-to-child transplantation for patients receiving
mother-donor grafts [28]. Two patients who rejected their ﬁrst allograft
underwent a second HSCT using the other haploidentical parent as a donor.
Each donor received granulocyte colony-stimulating factor by subcu-
taneous injection at a dose of 10 mg/kg/day. Donor peripheral blood stem
cells were collected via leukapheresis, starting on day 4 of granulocyte
colony-stimulating factor administration, and TCD by means of CD34þ cell
positive selection, using the CliniMacs one-step procedure (Miltenyi Biotech,
Bergisch Gladbach, Germany).Engraftment aGVHD cGVHD Follow-
Up (yr)
Outcome
Rejection Absent Absent 11.5 Alive and well
after 2nd HSCTEngraftment
Engraftment Absent Not assessable .3 Died from RSV
pneumonia
Engraftment Absent Limited 1.2 Alive and well
Engraftment Absent Absent 7.1 Alive and well
Engraftment Grade II Absent 7.1 Alive and well
Engraftment Absent Absent 3.3 Alive and well
Engraftment Grade I Limited 6.9 Alive, limited
cGVHD
Rejection Absent Absent .7 Alive and well
after 2nd HSCTEngraftment
Died before
engraftment
Not assessable Not assessable .03 Died from Candida
sepsis
Engraftment Absent Absent .5 Alive and well
Engraftment Grade II Limited 1.0 Alive and well
Engraftment Absent Absent 1.3 Alive and well
genous leukemia.
Table 2
Summary of Characteristics of Patients, Donors, and Transplantation
Procedures
Number of Cases
or Median
Percent
or Range
Patients 12 100
Males 4 33
Females 8 67
Age at diagnosis, yr 6.7 2.7-12.4
Age at HSCT, yr 8.6 5.9-21.7
Time from diagnosis to HSCT, yr 2.4 .3-19.0
Transfusion dependence 12 100
Clonal evolution at HSCT 2 17
Acute myeloid leukemia 1 8.5
T cell non-Hodgkin lymphoma 1 8.5
Donors* 14 100
Father 8 57
Mother 6 43
Donor age, yr 41 30-58
Sex mismatch, donor/ recipient*
Female/ male 1 7
Other combinations 13 93
HLA disparity*
A, B, C, and DRB1 antigen mismatch 11 79
A, B, C antigen mismatch, and
DRB1 match
1 7
A, B, and DRB1 antigen mismatch þ
C allele mismatch
1 7
B, C, and DRB1 antigen mismatch þ
A allele mismatch
1 7
NK-alloreactive donor*
Yes 7 50
No 7 50
Transplantation procedure
Conditioning regimen* 14 100
Flu þ Cy þ ATG þ TBI 11 79
Flu þ Cy þ ATG 3 21
Cell dose infused
CD34þ  106/kg 19.1 5.6-35.0
CD3þ  104/kg 1.4 .35-5.0
CD19þ  104/kg 4.7 1.8-21.0
TBI indicates total body irradiation.
* Fourteen transplants in 12 patients.
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The conditioning regimen consisted of i.v. Flu 30 mg/m2/day adminis-
tered for 4 consecutive days (days 6 to 3) and Cy 300 mg/m2/day for 4
consecutive days (day 6 and 3) along with hyperhydration and Mesna.
Pretransplantation Fresenius antithymocyte globulin (ATG) was adminis-
tered to all recipients at a dose of 10 mg/kg/day for 4 consecutive days from
day 6 to day 3. In 11 patients the preparative regimen also included
200 cGy single-dose total body irradiation to increase the immuno-
suppressive effect of the conditioning regimen and to reduce the risk of
rejection. Because of graft rejection requiring a second HSCT, 2 patients
underwent a second conditioning regimen based on the same drug com-
bination (Flu þ Cy þ ATG) without total body irradiation.
TCD peripheral blood stem cells were infused without prior cryopres-
ervation through a central venous catheter 72 hours after completion of the
preparative regimen. The TCD grafts contained amedian of 19.1106 (range,
5.6 to 35) CD34þ cells/kg recipient body weight. The median number of
CD3þ and CD19þ cells infused was 1.4  104/kg (range, .35 to 50) and
4.7  104/kg recipient body weight (range, 1.8 to 21), respectively. No
pharmacological immunosuppressive therapy was administered as post-
transplantation prophylaxis against GVHD.
Deﬁnition of Outcomes
The primary endpoints for survival analyses were transplant-related
mortality (TRM), deﬁned as the probability of death from any cause re-
lated to transplantation; overall survival (OS), deﬁned as the probability of
survival from the time of HSCT to death or last follow-up; and disease-free
survival (DFS), deﬁned as the probability of survival without evidence of
disease at any time after transplantation. In estimating DFS, death and
disease recurrence were considered events. Other endpoints included
event-free survival (EFS), deﬁned as the probability of survival from the time
of HSCT to the occurrence of any event (graft failure/rejection or death from
any cause) or the date of last follow-up; cumulative incidence of neutrophil
and platelet engraftment; median time to neutrophil and platelet recovery;cumulative incidence of acute and chronic GVHD (aGVHD, cGVHD); and
regimen-related toxicity.
The time to neutrophil engraftment was deﬁned as time from HSCT to
the ﬁrst of 3 consecutive days with an absolute neutrophil count .5109/L
and the time to platelet engraftment as time from HSCT to the ﬁrst of 7
consecutive days with an unsupported platelet count 50109/L. Transient
engraftment followed by peripheral blood count decline, with pancyto-
penia/marrow aplasia, absence of detectable donor cells in the recipient
blood, or autologous hematopoietic reconstitution, was considered as graft
rejection.
Post-transplantationmonitoring of donorerecipient chimerism, assessed
bymeans of quantitative analysis of PCR assay of short tandem repeatmarkers
in peripheral blood extracted DNA, was performed weekly from the day of
engraftment to day 100 and every 2 to 4 weeks until 12 months after trans-
plantation. Patients surviving for more than 7 and 100 days after the allograft
were evaluated for aGVHD and cGVHD occurrence, respectively. Severity of
aGVHD and cGVHD was assessed according to criteria from Glucksberg et al.
[29] and Shulman et al [30] respectively. Toxicity due to the preparative
regimen was graded using the system described by Bearman et al. [31].
Statistical Analysis
Continuous variables were described as median values and ranges,
whereas categorical variables were expressed as absolute values and per-
centages. Continuous variables were compared using the Mann-Whitney
test, whereas the Fisher exact test was used to compare categorical vari-
ables. OS, EFS, and DFS rates were expressed as 5-year probability and
calculated using theKaplan-Meiermethod [32]; the log-rank testwasused for
univariate comparisons. TRM, engraftment, rejection, grades II to IV aGVHD,
and cGVHD were expressed as cumulative incidences to adjust the estima-
tions for the pertinent competing risks [33,34]. For engraftment, aGVHD and
cGVHD death from any cause was considered a competing event; patients
surviving without GVHDwere censored at last follow-up. Comparisons of the
cumulative incidence estimates were made using Gray’s test. P < .05 were
considered to be statistically signiﬁcant and reported in detail; P  .05 were
reported as nonsigniﬁcant. Statistical analyses were performed with NCSS
(Copyright 2007 Dr. Jerry L. Hintze, Kaysville, UT 84037) and R 2.5.0 (http://
www.R-project.org) [35,36]. Analysis used January 31, 2013 as the reference
date.
RESULTS
Hematopoietic Recovery, Graft Rejection, and Chimerism
Hematopoietic recovery and sustained full-donor chime-
rismwere achieved in 9 of 12 patients (cumulative incidence
of engraftment equal to 75% [95% conﬁdence interval [CI], 54%
to 100%]). One patient died due to an opportunistic infection
on day þ12 after HSCT before engraftment had occurred.
Graft rejection, conﬁrmed by ampliﬁcation of short tandem
repeat markers showing 100% recipient chimerism, occurred
in 2 patients on days 16 and 17, respectively, after donor stem
cell infusion. Both were rescued by a second successful HSCT
(performed on days þ24 and þ25 after the ﬁrst HSCT,
respectively) using a TCD allograft from the other parent. The
cumulative incidence of graft rejectionwas 17% (95% CI, 5% to
59%) (Figure 1). In both cases, rejectionwas associated with a
number of CD34þ cells infused lower than 10  106/kg (5.6
and 8.9  106/kg, respectively), whereas the median number
of CD34þ cells infused in patients who achieved engraftment
(including the 2 patients retransplanted after the rejection of
the ﬁrst allograft who received at the time of second HSCT a
number of CD34þ cells infused at 25.0 and 31.0  106/kg,
respectively) was signiﬁcantly higher (median 24.5  106/kg
recipient body weight; range, 12 to 35) (P ¼ .026) (Figure 2).
On the contrary, no difference in the number of CD3þ lym-
phocytes infused was observed between patients who ach-
ieved engraftment (median, 1.4  104/kg; range, .34 to
5.03  104/kg) and the 2 who rejected the transplant (0.72
and 1.75  104/kg, respectively). Furthermore, both cases of
graft rejection occurred in patients transplanted from NK-
nonalloreactive donors.
The median time for neutrophil engraftment was 12 days
(range, 10 to 14 days), whereas the median time for platelet
Figure 1. Cumulative incidence of rejection (REJ) and TRM as well as Kaplan-
Meier probability of EFS, DFS, and OS for the whole study population.
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transplantation monitoring of donorerecipient chimerism
conﬁrmed the engraftment of donor hematopoiesis (100%
donor chimerism) in all patients.
Graft-versus-Host Disease
Three patients experienced aGVHD, with 1 patient devel-
oping grade I aGVHD and only 2 patients developing grade II
aGVHD. The cumulative incidence of aGVHD grade II was 17%
(95% CI, 5% to 59%). Of the 10 patients at risk, 3 developed
limited cGVHD (skin and/or liver involvement), with a
cumulative incidence of 35% (95% CI, 14% to 89%). No patient
experienced extensive cGVHD. No statistically signiﬁcant
associationwas found between the number of CD34þ or CD3þ
cells infused and the occurrence of aGVHD or cGVHD.
Regimen-Related Toxicity and TRM
The preparative regimen was fairly well tolerated. No
cases of regimen-related, fatal organ toxicity were observed.
Three patients developed grade III toxicities, namelymucosal
(n ¼ 1), gastrointestinal (n ¼ 1), and pulmonary toxicity
(n ¼ 1). Bladder toxicity was limited, with only 4 patients
with grade II and 2 patients with grade I toxicity.
One patient died of overwhelming Candida albicans sepsis
on day 12 after donor stem cell infusion before reconstitutionFigure 2. Median number and range of CD34þ cells infused in patients who
engrafted (24.5  106/kg; range, 12 to 35) and in the 2 patients who rejected
the graft (7.25  106/kg; range, 5.6 to 8.9). Mann-Whitney P ¼ .026.of granulopoiesis; another patient died on day 100 post-
transplantation because of respiratory failure associated
with a severe respiratory syncytial virus (RSV) infection,
despite successful engraftment. The 5-year cumulative TRM
incidence was 17% (95% CI, 5% to 59%) (Figure 1).
Survival
With amedian follow-up of 2.3 years (range, .6 to 11.5), the
Kaplan-Meier estimate of OS was 83% (95% CI, 62% to 100%)
(Figure 1). At 5 years after transplantation, the EFS probability
was 67% (95% CI, 40% to 93%) (2 cases of graft rejection and 2
transplant-related deaths were considered as events).
Nevertheless, because the 2 patients who rejected the graft
received a second successful HSCT, the probability of survival
without evidence of disease recurrence at any time post-
transplantation (DFS) coincided with OS and was 83% (95%
CI, 62% to 100%) (Figure 1). No case of secondary malignancy
was observed during the post-transplant follow-up.
Investigating the role of NK cell alloreactivity on trans-
plantation outcomes, we observed an EFS probability of 50%
(95% CI, 10% to 90%) in the 6 patients who received the ﬁrst
transplant from an NK nonalloreactive donor, whereas EFS
was 83% (95% CI, 54% to 100%) for the 6 patients who received
an NK-alloreactive graft (P ¼ nonsigniﬁcant).
DISCUSSION
In a considerable percentage of FA patients, a suitable
matched donor is not available or cannot be identiﬁed within
a reasonable time frame. Indeed, because the 25% theoretical
likelihood of having an HLA-identical sibling was found to be
reduced to less than 15%, due to the limited average size of
modern families in Western countries [37], and considering
that, in the case of a FA patient, the risk of each sibling to be
affected by the same disease is 25%, the probability of ﬁnding
a suitable HLA-identical, unaffected family donor is approx-
imately 10%. Moreover, the probability of ﬁnding a matched
unrelated donor or a matched cord blood unit within the
international volunteer registries is dictated by both the
patient’s HLA genotype frequency and ethnic background
[38]; further limitations derive from the often long duration
of the search, which may lead to disease progression or
clonal evolution. Furthermore, as a variety of factors such as
recipient’s age, extent of prior treatments and disease stage
has been shown to negatively affect the success of HSCT
[16,39], the rapid identiﬁcation of a potential donor and the
timing of HSCT appear to be critical to outcome.
In the absence of both an HLA-identical relative and a
matched unrelated volunteer or cord blood unit, HLA partially
matched family members can be used as alternative donors.
Haploidentical HSCT virtually ensures the opportunity for
nearly all patients to beneﬁt from HSCT and offers the advan-
tage of immediate accessibility to the transplant procedure.
Although the main obstacle to the success of related mis-
matched allografts has been the high incidence of graft rejec-
tion and severe GVHD, recent advances, including depletion of
alloreactive donor T lymphocytes from the graft, the use of
megadoses of stem cells, and the use of reduced-intensity
conditioning regimens, have signiﬁcantly decreased the early
TRM and GVHD [40]. In particular, in the setting of HSCT from
alternative donors, ex vivo TCD has been shown to be more
effective inpreventingGVHDthan the invivo administrationof
immunosuppressive drugs [41].
Although limited to case reports and small retrospective
case series, evidence from the medical literature supports
the use of haploidentical donors as a viable option in FA
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available [14,17-26]. The ﬁrst report of a successful hap-
loidentical HSCT in FAwas published in 2000 by Boulad et al.
[18], who used TCD stem cells from HLA-haploidentical rel-
atives to treat 2 patients with FA, the ﬁrst as a salvage therapy
for graft rejection of a ﬁrst unrelated cord blood allograft and
the second in a patient lacking an HLA-matched donor. Both
patients underwent a Flu-based preparative regimen con-
taining Cy and ATG together with total body irradiation. In
the same year, Elhasid et al. [19] described a 10-year-old girl
who rejected a ﬁrst HLA-mismatched allograft from her
mother after a conditioning containing Cy, ATG, and thor-
acoabdominal irradiation and was rescued by a second suc-
cessful TCD HSCT from her haploidentical father, following a
Flu-based preparative regimen. Successful engraftment after
a Flu-based conditioning that did not include radiotherapy
was reported in 2003 by our group in a patient with FA
treatedwith the infusion of amegadose of positively selected
CD34þ cells from a partially matched related donor [20].
After these early clinical experiences, a small number of
single case reports and case series were published describing
HSCT from related HLA-mismatched donors in FA patients
[21-25,42]. In the largest series reported to date, Locatelli
et al. [23], in an Italian retrospective multicenter analysis of
64 children with FA who underwent HSCT between January
1989 and December 2005, included 7 patients transplanted
from an HLA-haploidentical relative, with a reported esti-
mated 8-year OS rate of 69%.
In a recent study including 17 pediatric patients with
hematologic malignancies (n ¼ 14) and FA (n ¼ 3) under-
going haploidentical HSCT after T cell depletion by CD3þ
negative selection associated with in vivo B cell depletion
with rituximab, Dufort et al. [25] described the engraftment
of donor hematopoiesis in all FA patients with sustained
complete donor chimerism at 16, 6, and 5 months post-
transplantation, respectively. As an alternative to in vitro
T cell depletion, in 2012 Thakar et al. [26] explored the use of
low-dose post-transplantation Cy as a method to selectively
deplete activated alloreactive donor T cells in vivo in 3 FA
patients who received HLA-mismatched related marrow
grafts, reporting a rapid engraftment in all cases. Unfortu-
nately, 1 early transplant-related death from disseminated
toxoplasmosis and 1 case of severe aGVHD were observed
during the follow-up.
In this study, we report the outcome of 12 consecutive FA
patients treated with TCD HSCT from an HLA partially
matched related donor after a Flu-based preparative
regimen. This drug was previously shown to be sufﬁciently
immunosuppressive to overcome graft rejection, with a low
toxicity proﬁle. Consistent with data from the current liter-
ature, in our patient series this preparative regimen was
shown to be sufﬁciently immunosuppressive to allow the
engraftment of TCD stem cells; moreover, it was substantially
well tolerated, with no regimen-related grade IV toxicity
recorded and grade III toxicity observed in only 3 cases.
Furthermore, the same conditioning regimen was adminis-
tered before a second HSCT in 2 patients who rejected their
ﬁrst graft, without any additional toxicity.
A very high dose of hematopoietic cells is relevant to
ensure engraftment across the HLA barrier in the hap-
loidentical setting [43,44]. In our cohort, a median of 19 106
CD34þ cells/kg recipient body weight was infused, enabling
sustained engraftment with complete donor chimerism in
most cases. In line with this concept, graft rejection was
observed in the 2 patients who received the lowest CD34þcell dose (ie, <10  106 cells/kg recipient body weight),
whereas the median number of CD34þ cells infused in
patients who achieved sustained engraftment of donor he-
matopoiesis (including the 2 patients successfully retrans-
planted after the ﬁrst graft rejection) was signiﬁcantly
higher, conﬁrming the importance of stem cell dose for
engraftment.
In the setting of haploidentical HSCT, interactions be-
tween alloreactive donor NK cells and recipient cells, besides
protecting against leukemic relapse in malignant diseases,
could also mediate alloresponses instrumental for both the
clearance of host dendritic cells, critical in the pathogenesis
of GVHD, and the elimination of residual host T lymphocytes,
responsible for graft rejection [45,46]. Although the rela-
tively limited sample size of our cohort did not allow
detection of a possible NK alloreactivity effect on HSCT out-
comes, it is noteworthy that both cases of graft rejection
occurred in patients transplanted from a noneNK-allor-
eactive donor.
aGVHD accounts for a signiﬁcant part of the morbidity
and mortality associated with HSCT in FA patients, especially
in the context of transplantation from alternative donors
[23]. Previous evidence suggested that the underlying DNA
repair defect and enhanced tendency of FA cells to undergo
apoptosis might be relevant in promoting the high predis-
position of FA patients to develop severe aGVHD [47].
Furthermore, aGVHD strongly correlates with the develop-
ment of cGVHD in children [48], a condition that, in addition
to being a major cause of late morbidity and mortality after
allogeneic HSCT, has been shown to contribute to the
increased risk of developing late post-transplantation
malignancies, particularly squamous cell carcinomas. Donor
T cell depletion offers the potential for overcoming major
HLA barriers to enable transplantation of mismatched grafts,
thus reducing the risk of both aGVHD and cGVHD. In our
cohort, the cumulative incidence of aGVHD was only 17%
(with no case of grade III or IV aGVHD) and the incidence of
limited cGVHD was 35%, conﬁrming the efﬁcacy of T cell
depletion as sole GVHD prophylaxis. Despite the limited
cohort size and the relatively limited follow-up period, it
seems reasonable to hypothesize that such a low incidence of
GVHD may also positively inﬂuence the long-term risk of
developing post-transplantation epithelial cancers.
In conclusion, our data, obtained in the largest patient
series reported to date, demonstrate that HSCT from an HLA
partially matched family donor is a feasible and effective
option for the treatment of the hematological abnormalities
in FA patients. The combined effect of a reduced-toxicity
conditioning regimen with the infusion of large numbers of
CD34þ cells and a GVHD prophylaxis based on extensive
T cell depletion enabled stable engraftment to be achieved
over major HLA barriers, with high OS and DFS, acceptable
toxicity, and low rate of GVHD. Finally, the prompt avail-
ability of a related donormarkedly increases the likelihood of
transplantation before the administration of a large number
of transfusions, exposure to androgens, and, in most cases,
before the development of clonal hematopoietic disorders,
therefore preventing the occurrence of complications that
may negatively affect the success of HSCT and the long-term
outcome in patients with FA [11,39,49].
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